Semax is a synthetic peptide investigated for effects on nervous-system signaling and neurological outcomes. It is related to a fragment of adrenocorticotropic hormone but should not be assumed to reproduce all actions of that hormone. Its scientific interest and its clinical evidence are separate questions.

What has been studied

Experimental work in rats has examined changes in neurotrophin-related gene expression after cerebral ischemia. These studies can help generate hypotheses about mechanisms, but gene-expression changes in an injured rat brain are not proof of cognitive enhancement in healthy people. Semax and neurotrophin transcription in an ischemia model

Human reports also exist. A 2018 study examined 110 people during post-stroke rehabilitation and reported relationships among Semax exposure, plasma BDNF and functional measures. The accessible abstract does not establish the full safeguards needed to treat the result as definitive, and plasma BDNF is not a direct measurement of brain repair. Gusev and colleagues, 2018

What small imaging studies can tell us

A separate study assessed short-term resting-state brain-network changes in healthy participants. An imaging difference shows that a measured signal differed under the study conditions; it does not automatically demonstrate improved memory, attention or daily functioning. Lebedeva and colleagues, 2018

What should not be inferred

These findings do not justify describing Semax as a proven general “brain booster,” nor do they establish equivalence among formulations and routes. Reliable clinical conclusions require appropriate controls, adequate sample size, reproducible functional outcomes and systematic safety assessment.

Safety and U.S. regulatory context

FDA identifies potential immune reactions associated with peptide aggregation and peptide-related impurities for certain Semax administration routes. It reports absent or limited route-specific safety information, leaving insufficient evidence to determine whether administration would cause harm. FDA safety-risk assessment

As of November 4, 2026, HHS has also announced a draft, nonbinding 503A enforcement-discretion policy including Semax. This is not FDA approval or a final bulks-list rule. October 30 Federal Register notice Its accompanying document specifies Semax free base for intranasal use subject to patient-specific prescription, manufacturing, testing and other conditions. Those conditions do not establish general efficacy or eliminate safety uncertainty. HHS policy and appendices This is not a treatment recommendation.